Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial.

Di Rocco M, Forleo-Neto E, Pignolo RJ, Keen R, Orcel P, Funck-Brentano T, Roux C, Kolta S, Madeo A, Bubbear JS, Tabarkiewicz J, Szczepanek M, Bachiller-Corral J, Cheung AM, Dahir KM, Botman E, Raijmakers PG, Al Mukaddam M, Tile L, Portal-Celhay C, Sarkar N, Hou P, Musser BJ, Boyapati A, Mohammadi K, Mellis SJ, Rankin AJ, Economides AN, Trotter DG, Herman GA, O'Meara SJ, DelGizzi R, Weinreich DM, Yancopoulos GD, Eekhoff EMW, Kaplan FS

Open source

DOI: 10.1038/s41591-023-02561-8
Published: 2023 Oct
Container: Nature medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-023-02561-8,
  title = {Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial.},
  author = {Di Rocco M and Forleo-Neto E and Pignolo RJ and Keen R and Orcel P and Funck-Brentano T and Roux C and Kolta S and Madeo A and Bubbear JS and Tabarkiewicz J and Szczepanek M and Bachiller-Corral J and Cheung AM and Dahir KM and Botman E and Raijmakers PG and Al Mukaddam M and Tile L and Portal-Celhay C and Sarkar N and Hou P and Musser BJ and Boyapati A and Mohammadi K and Mellis SJ and Rankin AJ and Economides AN and Trotter DG and Herman GA and O'Meara SJ and DelGizzi R and Weinreich DM and Yancopoulos GD and Eekhoff EMW and Kaplan FS},
  year = {2023},
  journal = {Nature medicine},
  doi = {10.1038/s41591-023-02561-8},
  url = {https://doi.org/10.1038/s41591-023-02561-8}
}

RIS

TY  - JOUR
TI  - Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial.
AU  - Di Rocco M
AU  - Forleo-Neto E
AU  - Pignolo RJ
AU  - Keen R
AU  - Orcel P
AU  - Funck-Brentano T
AU  - Roux C
AU  - Kolta S
AU  - Madeo A
AU  - Bubbear JS
AU  - Tabarkiewicz J
AU  - Szczepanek M
AU  - Bachiller-Corral J
AU  - Cheung AM
AU  - Dahir KM
AU  - Botman E
AU  - Raijmakers PG
AU  - Al Mukaddam M
AU  - Tile L
AU  - Portal-Celhay C
AU  - Sarkar N
AU  - Hou P
AU  - Musser BJ
AU  - Boyapati A
AU  - Mohammadi K
AU  - Mellis SJ
AU  - Rankin AJ
AU  - Economides AN
AU  - Trotter DG
AU  - Herman GA
AU  - O'Meara SJ
AU  - DelGizzi R
AU  - Weinreich DM
AU  - Yancopoulos GD
AU  - Eekhoff EMW
AU  - Kaplan FS
PY  - 2023
JO  - Nature medicine
DO  - 10.1038/s41591-023-02561-8
UR  - https://doi.org/10.1038/s41591-023-02561-8
ER  -

APA

M, D. R., E, F., RJ, P., R, K., P, O., T, F., C, R., S, K., A, M., JS, B., J, T., M, S., J, B., AM, C., KM, D., E, B., PG, R., M, A. M., L, T., C, P., N, S., P, H., BJ, M., A, B., K, M., SJ, M., AJ, R., AN, E., DG, T., GA, H., SJ, O., R, D., DM, W., GD, Y., EMW, E., & FS, K. (2023). Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial.. Nature medicine. https://doi.org/10.1038/s41591-023-02561-8

Source records

pubmed · retrieved 2026-09-26T20:00:30.050Z